JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/55/0.1/15.08.25 | Market Closed - Börse Stuttgart 06:54:27 2024-07-01 EDT | ||
| 0.11 EUR | 0.00% |
|
| 1 month | -8.33% | ||
| 3 months | -81.03% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 0.11 | 0.00% |
| 24-06-28 | 0.11 | -8.33% |
| 24-06-27 | 0.12 | 0.00% |
| 24-06-26 | 0.12 | 0.00% |
| 24-06-25 | 0.12 | 0.00% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 06:54 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | J.P. Morgan |
| WKN | JB9NYJ |
| ISIN | DE000JB9NYJ2 |
| Date issued | 2024-01-10 |
| Strike | 55 $ |
| Maturity | 2025-08-15 (410 Days) |
| Parity | 10 : 1 |
| Emission price | 0.57 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.62 € |
|---|---|
| Lowest since issue | 0.099 € |
| Spread | 0.02 € |
| Spread % | 16.67% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.3
USD
Average target price
53.19
USD
Spread / Average Target
+28.80%
- Stock Market
- Warrants
- Warrant
